Filing search / Kineta, Inc. / "Innovation"

8-K

EX-99.1

KANT Kineta, Inc.

24 May 23

Regulation FD Disclosure

9:30am

the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation

8-K

EX-99.5

KANT Kineta, Inc.

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm

approved through an abbreviated regulatory pathway. The Biologics Price Competition and Innovation Act of 2009 (the “BPCIA”) was enacted as part … biosimilars and generic drugs, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health

8-K

EX-99.6

KANT Kineta, Inc.

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm

, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain its proprietary position in the field … , along with funding for such research; and (9) established a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services, or CMS

424B3

8jew1qm 548pswl3mm

10 Nov 22

Prospectus supplement

4:21pm

8-K/A

EX-99.3

qbtt onf7

3 Feb 21

Other Events

4:59pm